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IN 21 asthmatic subjects, several functions of
isolated peripheral neutrophils (chemokinesis
and chemotaxis toward 10% E. coli; superoxide
anion generation after PMA; leukotriene B4 (LTB4)
release from whole blood and isolated neutro-
phtls, before and after different stimuli) were
evaluated during an acute exacerbation of
asthma, and after 14- 54 days of treatment with
systemic glucocorticosteroids (GCS). During acute
exacerbation, superoxide anion generation was
higher in asthmatics than in eleven normal
subjects (39.2 14.1 vs. 25.2 +__ 7.3 nmol,p < 0.05);
there was a significant correlation between FEV1
(% of predicted) and neutrophil chemotaxis
(r---0.52, p--0.04). After treatment, there was
no significant change in aH neutrophil functions,
except for a decrease in neutrophil chemotaxis in
subjects who showed an FEV1 increase >20% after
GCS treatment (from 131 _+ 18 to 117 _+ 21 m,
p 0.005). Chemokinesis sicantly decreased
in all subjects, and the changes significantly cor-
related with an arbitrary score of the total admin-
istered dose of GCS (r 0.57,p < 0.05). These data
suggest that neutrophil activation plays a minor
role in asthma, and that treatment with GCS is
not able to modify most functions of peripheral
neutrophils in asthmatic subjects; chemotaxis
seems to be related only to the severity of the
asthma and it could reflect the improvement of
the disease.
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Introduction
Asthma has been defined as reversible airway
obstruction, associated with nonspecific bron-
chial hyperresponsiveness, which is sustained by
a chronic airway inflammation. Pathology of fatal
asthma
2 and direct in vivo measurements of
indices of airway inflammation by bronchoalveo-
lar lavage (BAL) and bronchial biopsy3’4 has con-
firmed the major role played by the recruitment
of inflammatory cells in the airways of subjects
with asthma of different severity.
While eosinophils are pivotal cells in asthma,
the role of neutrophils in the pathophysiology of
asthma is still uncertain. Neutrophil counts are
increased in bronchial (BL) and bronchoalveolar
lavage (BAL) of animals and humans after acute
exposure to allergens, chemicals (like toluene
diisocyanate, TDI) or oxidants (like ozone);5-7
but in the stable phase, asthmatics show neu-
trophil counts in BAL or in bronchial biopsy that
are not different from those found in normal
9 subjects.’ Markers of activation of neutrophils
have been inconsistently demonstrated in the
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blood of asthmatic subjects. Peripheral neu-
trophils of asthmatic subjects seem to have
higher releasability of mediators,
1-15 higher
superoxide anion generation
1 and higher migra-
tory activity
11 than in normal subjects. However,
the differences between asthmatic and normal
subjects are mild; the observed abnormalities are
not strictly related to the severity of asthma and
they do not change significantly with the treat-
ment of asthma. Thus, the significance of these
abnormalities in the pathophysiology of the
disease has not been demonstrated. Since neu-
trophils contain many destructive proteases and
are able to release arachidonic acid metabolites,
such as the potent chemoattractant leukotriene
B4 (LTB4), these cells can be considered to play
a pathologic role in asthma.
Glucocorticosteroids (GCS) and other anti-
inflammatory drugs now represent the first
choice in the treatment of asthma. The efficacy
of inhaled or systemic GCS can be evaluated by
the changes in pulmonary function tests and
bronchial reactivity, but also by the imjrovement
in the markers of airway inflammation. GCS can
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modify several functions of the inflammatory cells by i.m or oral route, or equivalent doses of
involved in asthma, and these effects can explain deflazacort (Flantadin, Lepetit, Italy). They were
the efficacy of these drugs in asthma treatment, examined every 2 weeks until a significant
Some in vitro studies have shown that GCS can improvement in asthma symptoms occurred. At
stabilize lysosomes, inhibit chemotaxis and other the end of the treatment period, they repeated
neutrophil functions,
7-2 but these effects occur pulmonary function tests and blood measure-
at very high concentrations of GCS, and their ments.
clinical significance has not been proven. Few in In the same time, eleven normal subjects from
vivo or ex vivo studies have evaluated the effect our Unit team were examined as regards the
of physiologically important concentrations of spontaneous and 20 I.tM calcium ionophore
GCS on neutrophil functions, showing effects on A23187-induced LTB4 release from whole blood,
some9-2 but not on other functions.8’22 migratory activity and superoxide anion genera-
The aim of our study was to assess whether tion of isolated peripheral neutrophils.
treatment with systemic GCS in subjects with
exacerbation of asthma was able to modify
several functions of peripheral neutrophils Mthod
potentially involved in the pathophysiology of
asthma, such as chemotaxis, release of oxygen Pulmonary function tests: Expiratory flow-
radicals and LTB4. Furthermore, the effect of volume curves were performed by means of a
GCS treatment on these neutrophil functions was HP Pulmonary Desk System 47804/A; three
related to the improvement in the airway acceptable manoeuvres were obtained each time,
obstruction as assessed by spirometry, according to ATS criteria.2
Haematology: Total and differential WBC count
Subjects in the blood was measured with a laser Coulter
(H1 Bayer, Basel, Switzerland).
Twenty-one non- or ex-smoker subjects (seven For the release of LTB4 from whole blood,
male and 14 female, with a mean age of 42 _+ 16 heparinized whole blood was incubated for 30
years) with moderate to severe bronchial asthma min at 37C in the presence of either 20 l.tM
were studied. Asthma diagnosis has been made calcium ionophore A 23187 (Sigma, St. Louis,
in the past on the basis of: (1) clinical history of MO, USA), or 0.2 mM N-formyl-methionyl-
wheeze, cough or shortness of breath; (2) leucyl-phenylalanine (f-MLP, Sigma) or 300 btg/ml
increase in FEV > 12% after acute administration zymosan (ZAS, Sigma). Control incubations were
of inhaled betai-agonists or after a short term performed in the absence of stimuli. After incu-
course of intensive treatment with bronchodila- bation, serum was obtained by centrifugation at
tors and GCS;23 or (3) methacholine PD20FEV 1 500 x g for 10 min and divided into aliquots
lower than 1 mg. The mean duration of asthma for subsequent eicosanoid assay. Leukotriene B4
was 11 4-9 years. At the time of the first (LTB4) concentration in the supernatant was
examination, all subjects were under regular measured using radioimmunoassay (RIA)with a
treatment with bronchodilators (inhaled beta2- tritiated tracer (Amersham, UK); an LTB4 stan-
agonists and/or oral theophylline) and inhaled dard was purchased from Upjohn (Kalamazoo,
anti-inflammatory drugs (sodium cromoglycate or MI, USA); and the specific antiserum was a gift
nedocromil sodium in eight subjects, beclo- from Dr Frank Carey and Dr Robert Forder, ICI
methasone dipropionate 800- 1500 lg daily in Pharmaceuticals, UK. The sensitivity of LTB4 RIA
13 subjects). The aetiology of asthma was allergic was 4.3 4- 0.9 pg (coefficient of intra-assay varia-
in eight subjects, occupational in two subjects, tion: 12%).
and intrinsic in the remaining eleven subjects.
The first examination was done when subjects Preparation of isolated neutrophils: For prepara-
experienced a spontaneous exacerbation of tion of granulocytes, ACD-anticoagulated blood
asthma, with increase in asthma symptoms (60ml) was centrifuged at 180 x g for 10 min;
despite their current treatment. At this time, they the supernatant platelet-rich plasma was dis-
performed spirometry and collected a blood carded, and the remaining aliquot was mixed
sample to measure total and differential white with a 3.5% solution of dextrane T500 (Pharma-
blood cells (WBC), migratory activity and other cia, Uppsala, Sweden) in saline solution, to a
markers of activity of peripheral neutrophils, final concentration of 1.5%. After allowing differ-
Systemic GCS were added to their regular treat- ential cell layering for 60 min at room tempera-
ment: 6-methyl-prednisolone (Urbason, Hoechst, ture, leukocyte-rich plasma was collected and
Italy) 40 mg/day for 3 days and then 20 mg/day centrifuged at 270 x g for 10 min; after dischar-
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ging the supernatant, the pellet was resuspended trifuged at 1 500 x g for 5 min at 4C to remove
in 7.5 ml phosphate-buffered saline without cells. The reduction of cytochrome C was mea-
calcium and magnesium (PBS, Sigma)containing sured by reading the adsorbance of the super-
0.5% bovine serum albumin (BSA), carefully nant at 550 nm wavelength. The intra-assay
layered onto 3.0 ml of Ficoll-Hypaque (Lym- variation was 4.9%.
phoprep, Nycomed AS, Oslo, Norway) and cen-
trifuged at 350 x g for 30 min. Mononuclear Release ofLTB4 after different stimuli. A suspen-
cells at the interface between PBS and Ficoll- sion of isolated granulocytes (concentration,
Hypaque were removed (see below); lysis of red 7.5 x 106 cells/ml) was incubated for 30 min at
blood cells was performed by adding 6 ml of 37C in the presence of either 20 btM calcium
distilled water to the pellet for 15 s, and osmo- ionophore A 23187, or 0.2 mM N-formyl-methio-
larity was re-equilibrated to normal levels with nyl-leucyl-phenylalanine, or 300 l.tg/ml zymosan.
2 ml of 3.5% NaC1 solution. After further cen- Control incubations were performed in the
trifugation (270 x g for 5 min), the final pellet absence of stimuli. At the end of the incubation,
was resuspended in 1 ml of PBS and cell count a supernatant was obtained by centrifugation at
performed in a Thoma-Zeiss microscope 1 500 x g for 10 min and divided into aliquots
chamber. Cell viability was evaluated by Trypan for subsequent eicosanoid assay. The LTB4 con-
blue exclusion and was always >95%. Neu- centration in the supernatantwas measured using
trophil purification, evaluated on a standard the same radioimmunoassay (RIA) as described
May-Grunwald-Giemsa smear, was also > 959/o. previously.
Purified neutrophils were used to perform
measurements of migratory activity, generation of Statistical analysis: Data are reported as mean _+
superoxide anion, and release of LTB4 after dif- standard deviation (S.D.). Paired and unpaired
ferent stimuli. Student’s t-tests were performed when appro-
priate. Regression analysis was used to correlate
Migratory activity. Chemokinesis and chemotaxis pulmonary function tests with indices of neutro-
of granulocytes were measured by a modified phil activity in the blood, a level of sigm4ficance
Boyden chamber technique. A 0.7 ml aliquot of a lower than 5% was considered significant.
cell suspension adjusted to 1 x 106/ml was put
into the upper compartment of a Boyden
chamber, using a 13 mm diameter and 3 lm Rult
pore size filter (Millipore Co, Bedford, USA).
Dulbecco solution or 109/o E. coli culture super- At the time of asthma exacerbation, all subjects
natant was placed in the lower compartment of were currently symptomatic with a moderate to
the chamber to study chemokinesis (random severe airway obstruction (mean FEVx,
migration) or chemotaxis, respectively. Incuba- 1.55 +_ 0.48 1, 51.1 __+ 15.1% of the predicted
tion was performed for 2 h at 37C in a CO2 value). Haematology showed high eosinophil
incubator. Filters were fixed on a microscope count (>400 cells/ll) in nine of 21 subjects
slide and stained with haematoxylin-eosin. (43%). The evaluation of the peripheral neutro-
Migration of granulocytes was measured accord- phil functions in the asthmatic subjects showed
ing to the ’leading-front’ technique on ten ran- no significant difference with respect to normal
domly selected low power (x 40) fields. All subjects as regards the spontaneous and 20 tM
samples were processed in triplicate. The intra- calcium ionophore A23187-induced LTB4 produc-
assay and inter-assay variations were 7% and 13%, tion from whole blood (2.1 ___
4.7 lag/ml and
respectively. 152.2 _+ 72.8 l.tg/ml in asthmatics, and
2.0 _+ 3.4 l.tg/ml and 93.1 +_. 23.8 tg/ml in normal
Generation of superoxide anion. Generation of subjects, respectively) and chemotaxis of isolated
superoxide anion was tested by incubating peripheral neutrophils (122.0_ 16.4 l.tm in asth-
0.7 ml of a suspension of granulocytes at matics, and 117.5 10.1 lm in normal subjects).
2.1 x 106 cells/ml for 15 min at 37C in a Generation of superoxide anion from isolated
shaking waterbath with 50 1 of 30 mg/ml cyto- peripheral neutrophils was significantly higher in
chrome C (Sigma) and 0.75 ml of 2 lag/ml pre- asthmatics (39.2 + 14.1 nmol) than in normal
warmed phorbol myristate acetate (PMA, Sigma). subjects (25.2 __+ 7.3 nmol, p < 0.05), and chemo-
In order to subtract any O2-dependent change in kinesis showed a trend in increasing in asthmatic
adsorbance, the same assay was also carried out subjects in comparison with normal subjects
in the presence of 10 btl of 3 mg/ml superoxide (91.6 _+ 15.6 lm vs. 86.4 _+ 6.8 lm, p 0.07).
dismutase. The reaction was stopped by placing In asthmatic subjects there was a mild sig-
the tubes in ice, and the suspension was cen- nificant inverse relationship between FEV (in %
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of the predicted value) and neutrophil chemo-
taxis (r -0.52, p 0.04).
At the end of the treatment with systemic GCS,
when symptoms of exacerbation were recovered
in all subjects, mean FEV and FVC significantly
increased with respect to the pre-treatment
values (Table 1). Haematology showed a signifi-
cant increase in total WBC and neutrophil count,
and a significant decrease in eosinophil count. A
significant reduction of neutrophil chemokinesis
was observed after treatment. No change was
observed in chemotaxis and superoxide anion
generation from isolated peripheral neutrophils
(Table 1).
The spontaneous and induced release of LTB4
from whole blood and from isolated peripheral
neutrophils was not significantly reduced after
treatment with GCS (Table 2). There was a sig-
nifican increase in LTB4 release from whole
blood after 20 btM calcium ionophore incubation
(from 152.2 ___
72.8 to 204.7 89.3 l.tg/tnl,
p< 0.001) and a trend for ZAS-induced LTB4
release (from 48.1 20.8 to 60.0 27.4 btg/ml,
p 0.08); this increase was not observed when
Table 1. Mean values (+ SD) of pulmonary function tests, blood
cell count, migratory activity and superoxide anion generation of
peripheral isolated neutrophils in 21 asthmatic subjects, before
and after treatment with systemic GCS
Parameter Before treatment After treatment
(n 21) (n 21)
FVC (%pred) 74.4 ___
16.3" 86.9 -t- 19.5
FEV1 (%pred) 51.1 + 15.1" 68.0 -I- 23.6
White blood cells (cells/ll) 7 470 -I- 2 757* 8 926 -t- 2 636
Neutrophils (cells/ll) 4 364 -I- 2 662* 5 660 + 2 862
Eosinophils (cells/ll) 501 -t- 428* 224 __+ 209
Neutrophil chemokinesis (tm)
Neutrophil chemotaxis (lm)
Superoxide anion generation (nmol)
91.6 -t- 15.6* 82.2 -t- 12.5
122.0 ___
16.4 118.6 -t- 14.0
45.4 23.2 43.8 -I- 22.5
*p < 0.05 between before and after treatment.
Table 2. Mean values (+ SD) of LTB4 release from whole blood
and from isolated peripheral neutrophils in 21 asthmatic
subjects, before and after treatment with systemic GCS
Stimulus Before treatment After treatment
(n 21) (n 21)
Whole blood-LTB4 release (lg/ml)
No stimulus 2.1 ___
4.7 1.3 1.2
20 iM calcium ionophore A23187 152.2 -t- 72.8* 204.7 + 89.3
FMLP 3.9 -I- 4.1 4.2 -I- 3.6
ZAS 48.1 20.8* 60.0 27.4
Isolated neutrophils-LTB, release (btg/ml)
No stimulus 0.5 __+ 0.6 0.5 -t- 0.9
20IM calcium ionophore A23187 50.0 + 42.3 56.9 -t- 32.6
FMLP 2.3 ___
2.9 2.3 + 2.2
ZAS 1.0 -I- 2.4 0.6 + 0.7
*p < 0.05 between before and after treatment values.
LTB4 release was obtained from isolated neu-
trophils.
At the end of.the treatment with systemic GCS,
ten subjects showed an increase in FEV greater
than 20% with respect to the pre-treatment eva-
luation; they were considered as responders. The
comparison between responders and non-
responders as regards haematology and indices
of neutrophil functions at the time of asthma
exacerbation showed that eosinophils were
higher in responders than in non-responders
(Table 3). No change in neutrophil functions was
observed after treatment in both groups, except
for a significant decrease in chemotaxis of iso-
lated peripheral neutrophils in responders (from
130.6 +_ 17.9 to 117.0 _+ 20.6 l.tm, p 0.005) but
not in non-responders. Total WBC and neu-
trophil counts increased after treatment, but the
changes were statistically significant only in non-
responders; eosinophils decreased significantly in
responders, and showed a trend (p 0.09) to
decrease in non-responders. No difference
between responders and non-responders could
be observed as regards the dose of oral GCS and
the duration of treatment (22.8 _+ 10.8 days in
responders vs. 24.1 +_ 12.6 days in non-respon-
ders).
An arbitrary score of the total dose of GCS
administered during all periods of treatment
(daily dose of 6-methyl-prednisolone or equiva-
lent dose of deflazacort x number of days of
treatment) was computed for each patient.
Responders had a similar score to non-respon-
ders. This score was not significantly related to
changes in the haematology or indices of neu-
trophil functions; there was only a significant
relationship between this score and the decrease
after treatment in chemokinesis from isolated
peripheral neutrophils (r 0.57, p < 0.05).
There was no difference in the changes of
indices of neutrophil activity between subjects
who received regular beta.-agonists in addition
to systemic GCS treatment and subjects who did
not, nor between subjects who were previously
treated with inhaled GCS and those treated with
cromones.
Discussion
We showed that treatment with systemic GCS,
at doses able to induce a significant improve-
ment in pulmonary function in asthmatic sub-
jects, was able to cause minimal effects on some
indices of activity of peripheral blood neu-
trophils. Chemotaxis towards E. coli endotoxin
was the only marker of neutrophil activity which
significantly reduced after GCS in subjects who
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Table 3. Mean values (-t- SD) of haematology, migratory activity and superoxide anion generation from isolated peripheral neutrophils
in asthmatic subjects who responded or not to systemic GCS treatment with an FEV1 increase of 20% or more
Responders Non-responders
(n-- 10) (n= 11)
Parameter Before After Before After
treatment treatment treatment treatment
FEV1 (%pred) 48 13 80 -t- 22* 54 17 57 -!- 20
White blood cells (cells/ll) 8208 -t- 3212 9686 -t- 2547 6 731 -t- 2 127 8285 -I- 2655*
Neutrophils (cells/ll) 4902 -i- 3206 5915-t- 2902 3827 +_ 2010 5451 ___
2952*
Eosinophils (cells/ll) 680 +__ 488 271 +__ 253* 323 -i- 279** 185 -I- 168
Chemokinesis (lm) 88.8 -!- 18,2 79.5 -t-_ 13.2 92.9 -t- 15.0 83.5 -I- 12.7
Chemotaxis (lm) 130.6 +__ 17.9 117.0 -t- 20.6* 117.7 +__ 14.6 119.4 10.7
Superoxide anion generation (nmol) 45.9 33,5 44.9 -t- 32.3 45.0 -t- 12.0 43.7 -t- 11.9
*p < 0.05 with respect to the pre-treatment evaluation; **p < 0.05 with respect to responders.
responded to GCS treatment with an increase in
FEV1, but no change in LTB4 release and super-
oxide anion generation from neutrophils was
observed. These data confirm and extend the
results obtained by Gin and coworkers19 on six
asthmatic patients; in particular, the effect was
obtained only in subjects clinically sensitive to
GCS and not in subjects who did not show any
significant change in FEV after treatment. There-
fore, the decrease in neutrophil chemotaxis
could be considered as a consequence of GCS
treatment on airway inflammation, and not as a
nonspecific effect of steroids directly on periph-
eral blood cells, because the same effect was not
observed in subjects who were non-responders
to GCS treatment, though they received similar
doses of GCS. On the other hand, chemokinesis
was affected by GCS in a dose-dependent
manner in all subjects, independently from the
degree of clinical response, suggesting that this
neutrophil function can be directly affected by
GCS and not by an effect on the mediators of
the asthmatic inflammation.
These results are in contrast with previous
reports, suggesting a lack of effect of GCS on
neutrophil locomotion in normal and asthmatic
subjects,18’25 but they agree with our previous
results obtained in asthmatic subjects tested with
high dose inhaled beclomethasone dipropionate
for 1 month.26
It is not surprising that some asthmatic
patients did not show a significant improvement
in FEV1 after GCS treatment. It is well known
that some patients are resistant to the steroids,
27
and that the effect of GCS on FEV can require a
different duration of treatment. Although all our
patients showed at the diagnosis the typical func-
tional abnormalities of asthma (reversibility and/
or bronchial hyperreactivity), it is possible that
some of them had a concomitant chronic
obstructive pulmonary disease of variable degree
which could contribute to the airway obstruction.
Patients who were responders to GCS showed, in
effect, higher eosinophil counts in the blood
than non-responders. Furthermore, the post-
treatment evaluation was performed after
improvement in symptoms, which could not cor-
respond to an improvement in pulmonary func-
tion. However, the duration of treatment and the
total administered dose of GCS were equivalent
in responders and non-responders, suggesting
that the lack of clinical response was not due to
an insufficient treatment in non-responders.
The lack of effect of GCS on LTB4 release
from whole blood and isolated neutrophils after
several stimuli confirm what has been previously
reported after a short-term treatment with GCS.
22
LTB4 release from neutrophils could be con-
sidered as a way to recruit new cells in the
airways after an initiating stimulus; because
neutrophils are usual inhabitants of the airways,
z8
this function could be physiologically important.
Although some methodological problems need
to be considered (the dose and the characteristic
of the different physiological and non-physiologi-
cal stimuli to induce LTB4 release from isolated
neutrophils), these results confirm a minor role
of neutrophil activation in asthma. The higher
release of LTB4 from whole blood after GCS is
due to the higher number of peripheral neu-
tr0Phils, induced by the well-known effect of
GCS on leukocyte margination. The different
increase in LTB4 release in whole blood and in
isolated neutrophils after the various stimuli was
due to the different amount of neutrophils
obtained in the different preparations, and to the
presence of platelets in whole blood which can
increase the availability of arachidonic acid as a
substrate for LTB4 production from neutrophil
lypoxygenase.
We must consider, however, that neutrophils
of the airways, obtained by bronchial or
broncho-alveolar lavage (BAL), could show a
higher degree of activation, and a greater mod-
Mediators of Inflammation Vol 4 1995 255P. L. Paggiaro et al.
ulation in their functions by anti-inflammatory
treatment, with respect to blood neutrophils.
Considering that several studies showed a good
correlation between activation of eosinophils
derived from the blood and from BAL fluid,29 the
difference between blood and BAL neutrophils,
although hypothetical, is not very probable.
As an additional finding, this study shows that
most functions of peripheral neutrophils from
asthmatic subjects during asthma exacerbations
are not different from those measured in a small
group of normal subjects, except for superoxide
anion generation. Furthermore, chemotaxis
toward E. coli endotoxin was significantly corre-
lated with an index of asthma severity like FEV.
The partial disagreement between previous
data1-6 and our observation regarding the
increased capability of peripheral neutrophils to
generate arachidonic acid metabolites and super-
oxide anion, could be explained by the small
group of normal subjects in our study, by some
methodological differences and by the different
severity of the disease.
In conclusion, our study shows that neutrophil
activation plays a minor role in asthma, and that
treatment with systemic GCS is not able to
modify most neutrophil functions in asthmatic
subjects. Chemotaxis only seems to be related to
the severity of asthma and it could reflect the
improvement of the disease after GCS treatment.
However, further studies on airway neutrophils
are needed.
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